Neurent Medical has secured a €25 million growth debt facility from Claret Capital Partners to accelerate commercialization of its NEUROMARK System for treating chronic rhinitis.
The financing will support continued commercial expansion of NEUROMARK, increased investment in sales and marketing, balance sheet strengthening and additional capital for future growth opportunities.
The debt facility follows Neurent Medical’s €62.5 million Series C financing completed earlier in 2026, giving the company additional resources to scale its minimally invasive treatment technology.
Neurent Medical’s flagship NEUROMARK System uses proprietary impedance-controlled radiofrequency technology to target hyperactive posterior nasal nerves associated with chronic rhinitis.
The technology is designed to provide durable relief from symptoms while offering a minimally invasive treatment option for patients with chronic inflammatory sinonasal disease.
Neurent is headquartered in Galway, Ireland, and maintains U.S. operations in Braintree, Massachusetts.
Claret Capital Partners focuses on growth debt for technology, life sciences and impact companies. The firm has invested more than €1.5 billion across more than 210 companies since 2013.
KEY QUOTES:
“This financing represents another important milestone for Neurent Medical as we continue to scale our commercial operations and expand patient access to NEUROMARK. We are delighted to deepen our relationship with Claret Capital Partners, whose continued support reflects confidence in our technology, clinical evidence, commercial progress and long-term vision. The facility provides significant financial flexibility while allowing us to continue executing our growth strategy with minimal dilution to shareholders.”
Brian Shields, CEO of Neurent Medical
“Neurent Medical has demonstrated exceptional progress in establishing NEUROMARK as a leading treatment option for chronic rhinitis. We are pleased to further support the company as it continues its commercial expansion and works to improve outcomes for millions of patients suffering from chronic rhinitis.”
Daniel Mallon, Principal at Claret Capital Partners
